At The Gene Sherpa, Steve Murphy points to a recent perspective in the New England Journal of Medicine that gives direct-to-consumer personal genome services a no-go. Contributing to the lack of enthusiasm for companies like 23andMe and Navigenics is the fear that they offer more uncertainty than anything else when put into the hands of physicians.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.